Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magnolia
2024-513992-42-00Phase 3Completed
- Sponsor
- Anthos Therapeutics
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial of abelacimab in venous thromboembolism (VTE), pulmonary embolism (PE) and deep vein thrombosis (DVT) (2 arms), sponsored by Anthos Therapeutics. Primary endpoint: Time to first event of centrally adjudicated VTE recurrence. Started Jul 2024; status: completed.
02
Drugs
abelacimab
03
Conditions
venous thromboembolism (VTE)pulmonary embolism (PE)deep vein thrombosis (DVT)
Beyond the preview
Go deeper on 2024-513992-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513992-42-00.